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Abstract
Background: Currently, there is limited evidence on the effectiveness of second-line antiretroviral therapy (ART) in
sub-Saharan Africa. To address this challenge, outcomes of second-line protease inhibitor (PI) based ART in Rwanda
were assessed.
Methods: A two-stage cluster sampling design was undertaken. 49 of 340 health facilities linked to the open-
source electronic medical record (EMR) system of Rwanda were randomly sampled. Data sampling criteria included
adult HIV positive patients with documented change from first to second-line ART regimen. Retention in care and
treatment failure (viral load above 1000 copies/mL) were evaluated using multivariable Cox proportional hazards
and logistic regression models.
Results: A total of 1688 patients (60% females) initiated second-line ART PI-based regimen by 31st December 2016
with a median follow-up time of 26 months (IQR 24–36). Overall, 92.5% of patients were retained in care; 83%
achieved VL ≤ 1000 copies/ml, 2.8% were lost to care and 2.2% died. Defaulting from care was associated with
more recent initiation of ART- PI based regimen, CD4 cell count ≤500 cells/mm3 at initiation of second line ART
and viral load > 1000 copies/ml at last measurement. Viral failure was associated with younger age, WHO stage
III&IV at ART initiation, CD4 cell count ≤500 cells/mm3 at switch, atazanavir based second-line ART and receiving
care at a health center compared to hospital settings.
Conclusions: A high proportion of patients on second-line ART are doing relatively well in Rwanda and retained in
care with low viral failure rates. However, enhanced understandings of adherence and adherence interventions for
less healthy individuals are required. Routine viral load measurement and tracing of loss to follow-up is
fundamental in resource limited settings, especially among less healthy patients.
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Background
According to the 2016 estimates of the Joint United Na-
tions Programme on HIV/AIDS (UNAIDS), 36.7 million
people lived with HIV globally, and approximately half
were on antiretroviral therapy (ART) [1, 2]. Sub-Saharan
Africa (SSA), in particular, accounts for more than 80% of
the global population of people living with HIV (PLHIV)
[3]. Since the introduction of ART in 1996, there have
been substantial declines in morbidity and mortality re-
lated to HIV [3, 4]. Despite this achievement, a consider-
able number of people have failed to maintain a sustained
virological and immunological response to ART [5].
The World Health Organization (WHO) recommends
the use of a two nucleoside/nucleotide reverse transcript-
ase inhibitors (NRTIs) backbone and a non-nucleoside/
nucleotide reverse transcriptase inhibitor (NNRTI) as a
first-line ART; The proposed switch to a second-line regi-
men comprises of a ritonavir-boosted protease inhibitor
(PI/r) with two NRTIs [6]. The number of PLHIV switch-
ing from first- to second-line ART regimens is increasing
and this shift is related to several factors. Primarily,
non-adherence to medication, as a result of, adverse
events or non-continuous medication access was reported
in many studies as the key cause of treatment failure [7].
Additionally, as ART scale-up in SSA and elsewhere was
initiated in 2004 [3, 4], more PLHIV began receiving treat-
ment. Unavoidably, even under optimal circumstances,
treatment failures will occur overtime, resulting in an
increase in the number of individuals in requiring
second-line ART. Other factors, such as increased resist-
ance testing, improved adverse events detection and en-
hanced country access to affordable medications will also
likely contribute to improved accessibility to second-line
ART [4].
Since the launch of second-line regimens in SSA, out-
comes of large-scale national ART programmes were
assessed only in a few studies [8–13]. Botswana and
Rwanda are two countries in SSA achieving the highest
ART coverage > 80% [1, 2]. Of the estimated 220,000
PLHIV in Rwanda, 175,398 (80%) were receiving ART by
December 2016 [9]. Rwanda, for example, has demon-
strated a high rate of patients on first-line ART (> 90%)
[14]. Similarly, the number of patients on second-line
ART in Rwanda has also increased substantially in the last
decade from 388 patients in 2007 to 7625 by the end of
December 2016, representing ~ 4% of all patients on ART.
Given this progression, the purpose of this study is to
assess the outcomes associated with the rapid expansion
of second-line ART access in Rwanda [15].
Methods
Study design and data sources
By the end of 2016, a total of 553 health facilities were
offering HIV treatment in Rwanda. Among them, 513
had enrolled 7625 patients on second-line ART. Since
the open-source electronic medical record (EMR) system
was available in only 340 of the 553 health facilities, this
constituted our sampling frame. A two-stage cluster
sampling design was undertaken to randomly select 49
of the 340 eligible sites where all patients were consid-
ered for analysis in a retrospective observational cohort
study using routinely collected program data.
A comprehensive list of health facilities providing
second-line ART in Rwanda was compiled using the
Health Management Information data hosted at the
Rwanda Biomedical Center. This list formed the basis of
our first sampling frame, which consisted of our ran-
domly selected sample of health facilities. We restricted
our selection to health facilities that had a fully function-
ing EMR system. There were no other expected differ-
ences with health facilities that were in the process of
EMR roll out. Our stratification was balanced, enabling
equal opportunity for the inclusion of urban, rural, small
and big sites.
Our data source consists of electronic medical records.
After selecting 49 sites, we determined the data sam-
pling criteria to include all adult patients (aged 15 years
or older) on second-line ART. The total number of
patient data used for the study was 1689, representing
about 25% of the total patients on second-line regimen
in Rwanda. We excluded from our analysis all patients
who had switched to third line ART. Since Rwanda is
currently in the process of transferring HIV related data
sources to a national electronic database, some data are
still stored locally. Two authors DS and VN visited all 49
health facilities and extracted data backups from EMR
local servers using mysql software and exported them to
STATA version 14 to conduct the analyses.
Study population and definitions
Our study included patients aged 15 years or older, who-
ever switched to second-line ART in 49 randomly
selected health facilities in Rwanda since the start of
second line program in 2004 until 31st December 2016.
First-line ART regimens were composed of one NNRTI
plus two NRTIs and second-line regimens were PI-based,
in accordance with national guidelines. Two key possible
reasons for change may be due to first-line treatment
failure (virological and/or immunological) or the result of
adverse-effects to any compound in first-line combina-
tions or prior exposure to antiretroviral drugs. The fre-
quency of CD4 cell count measurement was bi-annual
while viral load has been measured annually for most of
patients according to the national guidelines except in
exceptional circumstances guided by decision from indi-
vidual clinician.
We defined virological failure as having a viral load
(VL) > 1000 copies/mL after at least 12 months on
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second-line ART with self-reported good adherence to
medication (> 90% no dose missed). Viral load failure
was used as an approach to confirm treatment failure.
The VL suppression threshold of ≤1000 copies/mL and
undetectable VL < 20 copies/mL were in accordance with
the 2016 WHO consolidated guidelines on the use of
antiretroviral drugs for treating and preventing HIV
infection [6].
We defined retention as alive and in care on
second-line ART at the time of data collection (31st
December 2016) and with no met criteria for loss to
follow-up (having missed contact with the health facility
during 3 consecutive months). Deaths were assessed
using recorded medical data in the EMR, which included
deaths that occurred outside of the health facilities.
Deaths were recorded within the national mortality
registry. Both viral suppression and loss to care served
as the outcomes. The explanatory variables for this ana-
lysis were all measured at time of switch from first to
second line ART and included demographic variables
(age, sex, marital status, body mass index (BMI), clinical
variables (TB screening status, CD4 cell count, WHO
stage, viral load, date of ART initiation, type of ART
regimen), and health facility-level variables (type of
health facility: district hospitals, health centers and refer-
ral hospitals).
Statistical analyses
Data are presented as medians and interquartile ranges
(IQRs) for continuous variables and frequencies and per-
centages for categorical variables. Fisher’s exact test was
used to assess the association between outcome of inter-
est (retention and viral load suppression) and each pre-
dictor. We used multivariate Cox proportional-hazards
regression to analyze time to discontinuation (loss to
follow-up or death) on second-line ART. The regression
model included the following covariates: age, gender,
CD4 cell count strata, WHO clinical stage, ART regi-
mens, viral load, and type of health facilities at the time
of first ART. The overall dataset contained only one case
of missing value which was not considered for retention
outcome. We controlled all different antiretroviral back-
bones and PI based combinations for each individual pa-
tient to assess differences in ART formulations vis-à-vis
retention and viral suppression.
The proportional hazard model test was used to
ensure that the proportional assumption was met. For
model selection, we used Aikaike Information Criteria
(AIC) to identify the model that best-balanced parsi-
mony and minimized residuals.
To model virological suppression, multiple logistic re-
gression was used to analyze viral load suppression using
the latest viral measurements. Finally, we calculated the
probability of a subject not being suppressed given a set
of predictors in order to obtain adjusted coefficients.
The coefficients were expressed as adjusted odds ratios
(OR). The model diagnostics were performed to assess
the goodness of fit using Hosmer and Lemeshow test,
deviance, and Pearson’s Statistics. All analyses were
conducted using STATA statistical software, version 14.
Ethical approval
Data used for this study were anonymized, de-identified
and routinely collected programme data maintained by
the Rwanda Biomedical Centre, Division of HIV/AIDS,
STIs and Other Blood Borne Infections. No participants
were involved directly in the data collection therefore
their consent was waived by the Rwanda National Ethics
Committee which also approved the use of routine
programme data presented here. The Rwanda Ministry
of Health also granted approval for data access and use
to the principal investigator (SN) for the purposes of
improving programme performance in Rwanda.
Results
Among the 181,921 individuals on ART in Rwanda [9],
174,252 (95.8%) received first-line ART and 7625 (4.2%)
received second-line ART by 31st December 2016 while
44 patients were on third line ART [16]. Figure 1 pre-
sents a flow diagram of the second line ART Rwanda
study sites and the patient selection process.
In our analysis, 1688 eligible patients were included,
all of which had initiated second-line ART in 49 ran-
domly selected health facilities representing about 25%
of all patients on second-line ART nationwide. Table 1
presents the baseline characteristics of the selected pa-
tients. There were more women (60%) in the sample.
The median age range was 35–44 years and approxi-
mately 38% of patients had initiated ART at WHO stage
3 or 4. The majority of patients (64%) had initiated
second-line ART prior to 2010 resulting in median
follow-up time of 26 months (IQR 24–36).
In total, 1562/1688 (92.5%) individuals were retained
in care, 126 (7.5%) were loss to follow-up (5.2%) or had
died (2.2%). Retention appeared to be lowest among
those aged 25–34 years, who were single, and the least
healthy. Retention was 89.0% in individuals who were
underweight and 90.7% among patients screened positive
for tuberculosis, and 90.4% among those with CD4 cell
counts below 350 cells/mm3 at initiation of ART.
In all 1688 individuals, at least one viral load result
was available, regardless of whether patients had subse-
quently defaulted from care. Of these, 1387 of 1688
(83%) individuals were virologically suppressed (≤ 1000
copies/ml) at last follow-up, whereas 1056 (63%)
achieved undetectable viral loads (≤ 20 copies/ml). Viro-
logical failure with VL > 1000 copies/mL was found in
301 of 1689 (18%) individuals. Of all those retained in
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care, a higher proportion were virologically undetectable
at the time of the last available viral load test result
compared to those lost to care (64% vs 43%). Virological
failure was also higher among those who were lost to
care (35% vs 16%). Retention in care was 94% for those
who were virologically suppressed and 85% for those
who were not suppressed.
Hazards for defaulting from care
The predictors of defaulting from care are presented in
Table 2.
These included ART initiation period from 2010 to
2012 and from 2013 to 2016 relative to 2009 or earlier
(adjusted hazard ratios [HR] 2.43, 95% confidence inter-
val [CI] 1.47–4.01 and HR 2.49, 95% CI 1.00–6.18), CD4
cell count ≤500 cells/mm3 vs CD4 cell count > 500 cells/
mm3 at initiation (HR 2.12, 95% CI 1.20–3.75), lopina-
vir/ritonavir (LPV/r) vs. atazanavir/ritonavir (ATV/r)
based second-line regimen (HR1.91, 95% CI 1.08–3.40)
and viral load > 1000 copies/ml vs ≤ 1000 copies/ml at
latest measurement (HR 2.60, 95% CI 1.71–3.94). In
addition to these clinical variables, being married or
cohabitating with a partner, relative to being single, was
protective of defaulting from care (HR 0.48, 95% CI
0.26–0.90).
Risk factors for virological failure
The following risk factors were associated with virological
failure in multivariate analysis: Age groups 15–29 years
and 30–39 years compared to age group 40–59 years (ad-
justed odds ratios (OR): 2.22, 95% CI 1.46–3.38 and OR
1.45, 95% CI 1.03–2.05), CD4 cell count ≤500 cells/mm3
vs. CD4 count > 500 cells/ mm3 at ART initiation (OR
5.40, 95% CI: 3.75–7.77), WHO stage III & IV care com-
pared to WHO stage I and II at programme enrollment
(OR, 1.56, 95% CI 1.18–2.06), ATV/r compared to LPV/r
based second-line regimen (OR 1.48, 95% CI 1.12–1.95)
and receiving care at a health center relative to regional or
provincial hospital (OR 1.55, 95% CI 1.11–2.17).
Discussion
Our study is the first to report on retention and viral
load outcomes using a national representative sample of
second-line ART patients in Rwanda. We found that,
overall, a high proportion of patients were retained in
care after a median follow-up of 26 months. The
estimated 92.5% retention was higher than that reported
in previous studies in similar settings [10, 17]. High re-
tention in care in the Rwanda HIV programme was also
previously reported [9, 18]. Several possible reasons for
high rates of retention in care include the highly decen-
tralized health system that provides easy to access HIV
Fig. 1 Flow diagram of Second line ART in Rwanda study sites and patients selection process
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Table 1 Baseline characteristics of patients on second-line ART in Rwanda stratified by retention and viral suppression
Characteristics Total Retained Defaulting from care Viral load suppression (copies/ml)
Alive LTFU Died Total ≤ 1000 > 1000
n (%) n (%) N (%) n (%) n (%) n (%) n (%)
Median age (IQR) 41 (33,49)
Age category(year)
15–29 327 (19) 300 (92) 24 (7) 3 (1) 327 (19) 242 (74) 85 (26)
30–39 426 (25) 390 (92) 28 (7) 8 (2) 426 (25) 344 (81) 82 (19)
40–59 841 (50) 785 (93) 35 (4) 21 (2) 842 (50) 718 (85) 124 (15)
60+ 94 (6) 87 (93) 2 (2) 5 (5) 94 (6) 84 (89) 10 (11)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
Sex
Female 1031 (61) 952 (92) 55 (5) 24 (2) 1032 (61) 866 (84) 166 (16)
Male 657 (39) 610 (93) 34 (5) 13 (2) 657 (39) 522 (79) 135 (21)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
Marital status
Single 344 (20) 309 (90) 27 (8) 8 (2) 344 (20) 259 (75) 85 (25)
Married/Cohabitating 648 (38) 602 (93) 30 (5) 16 (2) 649 (38) 540 (83) 109 (17)
separated/Divorced 98 (6) 89 (91) 7 (7) 2 (2) 98 (6) 86 (88) 12 (12)
Widowed 226 (13) 214 (95) 6 (3) 6 (3) 226 (13) 198 (88) 28 (12)
Missing 372 (22) 348 (94) 19 (5) 5 (1) 372 (22) 305 (82) 67 (18)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
ART Initiation period
2009 and before 1062 (63) 1004 (95) 34 (3) 24 (2) 1063 (63) 892 (84) 171 (16)
2010–2012 502 (30) 447 (89) 44 (9) 11 (2) 502 (30) 400 (80) 102 (20)
2013–2016 123 (7) 110 (89) 11 (9) 2 (2) 123 (7) 96 (78) 27 (22)
Total 1687 (100) 1561 (93) 89 (5) 37 (2) 1688 (100) 1388 (82) 300 (18)
TB Screening
Negative 1458 (86) 1356 (93) 75 (5) 27 (2) 1459 (86) 1213 (83) 246 (17)
Positive 151 (9) 138 (91) 8 (5) 5 (3) 151 (9) 111 (74) 40 (26)
N/A 79 (5) 68 (86) 6 (8) 5 (6) 79 (5) 64 (81) 15 (19)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
Body mass index
Normal weight 964 (57) 894 (93) 50 (5) 20 (2) 965 (57) 783 (81) 182 (19)
Underweight 186 (11) 165 (89) 13 (7) 8 (4) 186 (11) 144 (77) 42 (23)
overweight & Obese 538 (32) 503 (93) 26 (5) 9 (2) 538 (32) 461 (86) 77 (14)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
Median CD4 (IQR) 418 (248, 618)
> 500 cells/mm3 638 (38) 606 (95) 26 (4) 6 (1) 638 (38) 599 (94) 39 (6)
≤ 500 cells/mm3 1050 (62) 956 (91) 63 (6) 31 (3) 1051 (62) 789 (75) 262 (25)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
WHO stage
Stage 1–2 1042 (62) 971 (93) 51 (5) 20 (2) 1042 (62) 881 (85) 161 (15)
Stage 3–4 623 (37) 570 (91) 36 (6) 17 (3) 624 (37) 489 (78) 135 (22)
missing 23 (1) 21 (91) 2 (9) 0 (0) 23 (1) 18 (78) 5 (22)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
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services (98% of health facilities in Rwanda offer inte-
grated, comprehensive HIV services). Further, there is a
strong network of PLHIV that supports peer adherence
to medication including home visits, awareness and edu-
cation activities in the communities. In addition, Rwanda
has a robust electronic monitoring and surveillance
system that allows early warning signs of lost to care,
which initiates home visits by health care providers.
Finally, health care seeking behavior in the Rwandan
PLHIV population is high [9].
Our study identified key factors associated with
defaulting from care: initiating at higher viral loads, low
CD4 cell count, less clinical engagement, and time of
treatment switch. Other studies from SSA and Asia have
investigated predictors of attrition in care [10, 19–22].
Across many settings, loss to follow-up on second-line
patients was significantly higher among those with low
CD4 cell count at baseline, and previously undiagnosed
treatment failure on a first-line regimen [20–29]. Other
findings in similar settings reported that advanced
disease at initiation was associated with attrition on
second-line ART, and is likely the result of mortality
[30], as well as higher viral load and age [20]. Studies
from Malawi [21], Thailand [22] and South Africa [24]
reported that adherence was the major determinant of
treatment failure.
In this study, viral suppression rate (VL ≤ 1000 copies/
mL) among second-line patients in Rwanda was
estimated to be 83%. This rate is consistent with similar
results observed in other resource limited settings with
an average of 80% viral suppression after 12 months on
second-line ART [19, 31]. Results obtained from this
study are generally consistent with other studies in de-
veloping countries. For example, the pooled proportion
of virological failure in a recent systematic review and
meta-analysis on second-line ART in low- and
middle-income countries was 23.1, 26.7 and 38.0% at 12,
24 and 36months, respectively [18]. In many settings,
virological failure was observed in the first 6 months
following second-line ART start [18]. However, the re-
ported results had large variations between studies and
comparison of treatment failure might be difficult due to
different cut offs used for viral load suppression across
countries [32, 33].
Patients who were lost to care were more likely to be
viraemic than patients who were retained in care – a
finding observed also by others [34]. This has important
implications for evaluating progress towards the
UNAIDS 90–90-90 targets. For instance, assessing viro-
logical suppression (the third 90) only among patient
retained in care will overestimate success unless losses
to care are taken into account.
In Rwanda, a previous study reported that only 23% of
patients presenting virological failure (> 1000 copies/mL)
had drug resistance mutations suggestive of third line
ART, though 77% with high viral load could still remain
on efficacious second-line therapy [18, 35]. This
reinforces the need for intensive adherence for patients
presenting suboptimal viral load suppression before
switching to costly and complicated salvage therapies.
The same challenge was also reported in other
resource-limited countries [19, 29, 35].
Table 1 Baseline characteristics of patients on second-line ART in Rwanda stratified by retention and viral suppression (Continued)
Characteristics Total Retained Defaulting from care Viral load suppression (copies/ml)
Alive LTFU Died Total ≤ 1000 > 1000
n (%) n (%) N (%) n (%) n (%) n (%) n (%)
Second-line ARV regimen
LPV/r + dual NRTI 1097 (65) 1011 (92) 55 (5) 31 (3) 1098 (65) 920 (84) 178 (16)
ATV/r + dual NRTI 591 (35) 551 (93) 34 (6) 6 (1) 591 (35) 468 (79) 123 (21)
Total 1688 (100) 1562 (93) 89 (5) 37 (2) 1689 (100) 1388 (82) 301 (18)
Median VL (IQR) 20 (20, 100)
Viral load results
≤ 20 copies/mL 1056 (63) 1002 (95) 43 (4) 11 (1)
21–1000 copies/mL 331 (20) 303 (92) 20 (6) 8 (2)
> 1000 copies/mL 301 (18) 257 (85) 26 (9) 18 (6)
Total 1688 (100) 1562 (93) 89 (5) 37 (2)
Retention
Retained 1562 (93) 1305 (84) 257 (16)
Not retained 126 (7) 82 (65) 44 (35)
Total 1688 (100) 1387 (82) 301 (18)
VL viral load, TB tuberculosis, BMI body mass index, ART antiretroviral therapy, WHO World Health Organization, ATV/r ritonavir boosted atazanavir, LPV/r ritonavir
boosted lopinavir, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, IQR interquartile range, LTFU lost to follow-up
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The HIV programme in Rwanda has made major shifts
since 2009, when no new drug classes were available for
cases of virological failure [20]. The new recommenda-
tion was implemented in 2013, when LPV/r based regi-
mens were replaced by ATV/r based regimens. In our
analysis, patients who started anti-retrovirals after 2010
had better retention on ART, yet no better VL
outcomes.
For this study, we controlled the distributions of
backbones for both LPV/r and ATV/r. There was equal
distribution of zidovudine, tenofovir and abacavir for
each PI-based combination; lamivudine was maintained
Table 2 Predictors of attrition and virological failure on second-line ART
Predictors Multivariate analysis
Defaulting from care Virological failure
Adjusted hazard ratio (95% CI) p-value Adjusted odds ratio (95% CI) p-value
Age category (years). Reference category Age 40–59 a
15–29 years 0.85 (0.42, 1.71) 0.654 2.22 (1.46, 3.38) < 0.001
30–39 years 1.03 (0.58, 1.81) 0.930 1.45 (1.03, 2.05) 0.032
60+ years 1.87 (0.80, 4.38) 0.147 0.74 (0.36, 1.53) 0.421
Sex a
Male vs. female 0.87 (0.53, 1.43) 0.585 1.07 (0.80, 1.43) 0.644
Marital status. Reference category single a
Married/Cohabitating 0.48 (0.26, 0.90) 0.023 0.96 (0.64, 1.45) 0.857
Separated/Divorced 0.69 (0.24, 1.96) 0.487 0.56 (0.27, 1.14) 0.110
Widowed 0.57 (0.24, 1.34) 0.197 0.71 (0.40, 1.26) 0.242
Missing 0.31 (0.15, 0.65) 0.002 1.02 (0.68, 1.54) 0.916
ART initiation. Reference category 2009 and before a
2010–2012 2.43 (1.47, 4.01) 0.001
2013–2016 2.49 (1.00, 6.18) 0.049
TB Screening. Reference category TB negative +
Positive 1.26 (0.64, 2.49) 0.504 1.40 (0.92, 2.13) 0.117
No screening 3.04 (1.49, 6.22) 0.002 1.01 (0.54, 1.88) 0.979
BMI category. Reference category recommended weight +
Underweight BMI< 1.94 (1.05, 3.57) 0.034 0.99 (0.66, 1.50) 0.965
Overweight BMI > 1.23 (0.73, 2.06) 0.432 0.80 (0.59, 1.09) 0.155
CD4 Category +
≤ 500 copies vs. > 500 cells/mm3 2.12 (1.20, 3.75) 0.009 5.40 (3.75, 7.77) < 0.001
WHO Stages. Reference category Stage 1–2 a
Stage 3–4 1.22 (0.77, 1.96) 0.399 1.56 (1.18, 2.06) 0.002
Missing 0.49 (0.06, 3.73) 0.489 1.36 (0.46, 3.99) 0.574
Second-line regimen +
ATV/r + 2 NRTI vs. LPV/r + 2 NRTI 0.52 (0.29, 0.93) 0.027 1.48 (1.12, 1.95) 0.005
Viral load suppression +
> 1000 copies/mL vs≤ 1000 copies/mL 2.95 (1.83, 4.76) < 0.001
Health facility types +
HC vs. RH/PV 0.93 (0.52, 1.65) 0.799 1.55 (1.11, 2.17) 0.010
DH vs. RH/PV 1.23 (0.68, 2.22) 0.496 0.92 (0.63, 1.34) 0.653
a variable measured at initiation of ART, + variable measured at switch to second line ART
CI confidence interval, DH district hospital, HC health centre, PH provincial hospital, RH regional hospital, TB tuberculosis, BMI body mass index, ART antiretroviral
therapy, WHO World Health Organization, ATV/r ritonavir boosted atazanavir, LPV/r ritonavir boosted lopinavir, NRTI nucleoside/nucleotide reverse
transcriptase inhibitors
BMI categories: underweight ≤18.5 kg/m2, normal weight = 18.5–24.9 kg/m2, overweight& obesity =25 kg/m2 or greater
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across all second-line regimens as per national guide-
lines. Patients treated with ATV/r were significantly
more likely to experience virological failure. A recent
systematic review of six randomized controlled trials on
the comparative efficacy of second-line ART did not find
a difference in efficacy between LPV/r or ATV/r plus
two NRTIs and LPV/r with raltegravir. Although ATV/r
had a greater numerical efficacy compared to LPV/r, dif-
ferences were not statistically significant [25]. Another
study conducted in Uganda [26] compared LPV/r and
ATV/r in patients failing first line ART (2NRTI +
1NNRTI) and confirmed comparable potency and effi-
cacy. Being on LPV/r was twofold associated with default-
ing from care, which could be due to the higher pill
burden and adverse gastro-intestinal drug reactions asso-
ciated to LPV/r causing low adherence to medication [36].
A recent study in Malawi among patients receiving ATV/r
also reported that bilirubin levels predicted VL failure
[27]. ATV/r prescription with related increased bilirubin
has been associated with high interpatient disparities with
hyperbilirubinemia and jaundice resulting into premature
discontinuation of atazanavir and subsequently impact on
virological outcome [28].
A major strength of our analyses is the relatively large
sample size corresponding to 25% of all people living
with HIV on second-line ART in Rwanda. We also used
routinely reported data that reflects more precisely the
everyday life of patients. In addition, we had few missing
data and all our patients had at least one viral load mea-
sured in the last 12 months on ART. Data were collected
from a diverse population of patients in large, medium
and small sites. In addition, we managed to successfully
demonstrate how nationwide routine surveillance open
MRS data could be used to inform on patients’ retention
and viral load suppression.
Our study also has several limitations. First, the data
was collected from an open electronic medical record
system for which individual patient-level data were rou-
tinely reported. As such, not all desired variables were
available – most importantly adherence to HIV medica-
tion and outcomes among those lost to care. Second, we
could not distinguish reasons for switching to
second-line ART other than virological failure. Third,
the sampling population only included 340 of the 513
health facilities with second-line patients. Thus, there is
a risk of selection bias innate to the data availability. Fi-
nally, as with all observational studies, confounding
through unmeasured covariates need to be considered
when interpreting the reported associations.
Conclusions
In conclusion, our study suggests that patients on
second-line ART within Rwanda are doing relatively
well, with high levels of retention in care and viral
suppression. A better understanding of adherence and
adherence interventions for those that are less healthy is
required. Importantly, routine viral load measurement
and tracing of loss to follow-up is fundamental in
resource limited settings in order to minimize the risk of
treatment failure.
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